Toronto, Canada (PRWEB) November 08, 2013
Despite the growing prevalence of diabetes around the world, clinical trials face significant recruitment challenges brought on by increasing competition for patients, eligibility criteria and stricter regulatory requirements. Well over 200 drugs are currently in development for diabetes and related conditions. Given this level of drug development activity, as many as 500,000 patients are needed to enroll in these trials. To reduce the risk of costly enrollment delays, tailored recruitment strategies need to proactively address protocol challenges, consider patient motivations and complement local recruitment practices.
Missing data may also have costly consequences at the end of a study. Retention of patients has been recently highlighted by regulatory pressures to collect final status on outcomes trials. To reduce the risk of dropout or lost to follow-up, addressing protocol challenges up front may help to mitigate this risk. Retention strategies should be designed to reduce barriers to enrollment, promote protocol compliance and ensure a means of follow up with patients.
The discussion will include ways to develop targeted strategies with the potential to increase enrollment rates and reduce lost to follow-up by:
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
Read the full story at http://www.prweb.com/releases/2013/11/prweb11309631.htm.
Copyright©2012 Vocus, Inc.
All rights reserved